Causes of secondary ITP in adults
| Cause* . | ICD10 codes . | n . | Percent of secondary ITP (n = 518) . | Percent of ITP (n = 2882) . |
|---|---|---|---|---|
| In situ neoplasms | D00-D09 | 1 | 0.19% | 0.03% |
| Malignant neoplasms | C00-C97 | 314 | 60.62% | 10.89% |
| Hematological malignancies | C77, C81-C96 | 196 | 37.84% | 6.80% |
| Lymphoma | C77, C81-C86 | 91 | 17.57% | 3.16% |
| Hodgkin lymphoma | C81 | 16 | 3.09% | 0.55% |
| B-cell chronic lymphocytic leukemia | C91.1 | 49 | 9.46% | 1.70% |
| Multiple myeloma and malignant plasma cell neoplasms | C90 | 16 | 3.09% | 0.55% |
| Waldenström macroglobulinaemia | C88.0 | 13 | 2.51% | 0.45% |
| Myelodysplastic syndromes | D46 | 67 | 12.93% | 2.32% |
| Antiphospholipid syndrome | D68.6 | 8 | 1.54% | 0.28% |
| Viral hepatitis C or B | B16, B18.0-B18.2 | 9 | 1.74% | 0.31% |
| Viral hepatitis C | B18.2 | 5 | 0.96% | 0.17% |
| Viral hepatitis B | B16, B18.0-B18.1 | 4 | 0.77% | 0.14% |
| Human immunodeficiency virus disease | B20-B24 | 27 | 5.21% | 0.94% |
| Connective tissue disease | M32-M35.1 | 71 | 13.71% | 2.46% |
| Systemic lupus erythematosus | M32 | 49 | 9.45% | 1.70% |
| Systemic sclerosis | M34 | 3 | 0.58% | 0.10% |
| Dermatopolymyositis | M33 | 2 | 0.39% | 0.07% |
| Sicca syndrome | M35.0 | 16 | 3.09% | 0.55% |
| Mixed connective tissue disease | M35.1 | 3 | 0.58% | 0.10% |
| Rheumatoid arthritis | M05, M06.0, M06.2-M06.3, M06.8-M06.9 | 11 | 2.12% | 0.38% |
| Sarcoidosis | D86 | 18 | 3.47% | 0.62% |
| Immunodeficiency† | D80-D84 | 49 | 9.46% | 1.70% |
| Cause* . | ICD10 codes . | n . | Percent of secondary ITP (n = 518) . | Percent of ITP (n = 2882) . |
|---|---|---|---|---|
| In situ neoplasms | D00-D09 | 1 | 0.19% | 0.03% |
| Malignant neoplasms | C00-C97 | 314 | 60.62% | 10.89% |
| Hematological malignancies | C77, C81-C96 | 196 | 37.84% | 6.80% |
| Lymphoma | C77, C81-C86 | 91 | 17.57% | 3.16% |
| Hodgkin lymphoma | C81 | 16 | 3.09% | 0.55% |
| B-cell chronic lymphocytic leukemia | C91.1 | 49 | 9.46% | 1.70% |
| Multiple myeloma and malignant plasma cell neoplasms | C90 | 16 | 3.09% | 0.55% |
| Waldenström macroglobulinaemia | C88.0 | 13 | 2.51% | 0.45% |
| Myelodysplastic syndromes | D46 | 67 | 12.93% | 2.32% |
| Antiphospholipid syndrome | D68.6 | 8 | 1.54% | 0.28% |
| Viral hepatitis C or B | B16, B18.0-B18.2 | 9 | 1.74% | 0.31% |
| Viral hepatitis C | B18.2 | 5 | 0.96% | 0.17% |
| Viral hepatitis B | B16, B18.0-B18.1 | 4 | 0.77% | 0.14% |
| Human immunodeficiency virus disease | B20-B24 | 27 | 5.21% | 0.94% |
| Connective tissue disease | M32-M35.1 | 71 | 13.71% | 2.46% |
| Systemic lupus erythematosus | M32 | 49 | 9.45% | 1.70% |
| Systemic sclerosis | M34 | 3 | 0.58% | 0.10% |
| Dermatopolymyositis | M33 | 2 | 0.39% | 0.07% |
| Sicca syndrome | M35.0 | 16 | 3.09% | 0.55% |
| Mixed connective tissue disease | M35.1 | 3 | 0.58% | 0.10% |
| Rheumatoid arthritis | M05, M06.0, M06.2-M06.3, M06.8-M06.9 | 11 | 2.12% | 0.38% |
| Sarcoidosis | D86 | 18 | 3.47% | 0.62% |
| Immunodeficiency† | D80-D84 | 49 | 9.46% | 1.70% |